Two years after a campaign pledge that the federal government or insurers would cover the full cost of in vitro fertilization, no such requirement exists, and fertility advocates say patients are still waiting, according to NBC News.
What did happen is narrower and real. The cash price of three widely used fertility injectables has fallen steeply under a federal drug pricing agreement, and self-pay patients who use those specific medications are paying meaningfully less than they were a year ago.
Both halves of that record matter to a household budgeting for treatment, and they are routinely blurred together. A drug discount and a coverage mandate are different instruments that solve different problems. One reduces a line item. The other determines whether anyone besides the patient pays the bill.
Two Different Promises, Only One Partially Delivered
The campaign commitment was explicit. Speaking in Michigan in 2024, the president said the government would pay for IVF treatment or, as he put it in remarks replayed by PBS NewsHour, "we're going to be mandating that the insurance company pay."
An executive order followed in February 2025. It directed agencies to produce policy recommendations to protect IVF access and reduce costs within 90 days. It did not change any law, require any coverage, or appropriate any money, and CBS News has reported that the resulting recommendations were never publicly released.
The substantive follow-up came eight months later. In October 2025, the White House announced an agreement with EMD Serono, a leading fertility drug manufacturer, to sell three of its medications at most-favored-nation pricing through a federal website, and separate guidance clarifying how employers could offer standalone fertility benefits. The administration's fact sheet said the deal would result in significant savings on fertility treatments. EMD Serono said patients using all three of its therapies in a typical protocol would see an 84 percent discount off list prices.
The drug portion delivered. TrumpRx.gov went live in early February 2026, listing fertility medications among dozens of drugs. Gonal-F, whose list price tops $900, is listed at $168. The site does not sell medication; patients are redirected to the manufacturer's savings program to obtain a coupon redeemable at participating pharmacies, and a valid prescription is required.
By May, EMD Serono said more than 19,000 patients had accessed its fertility therapies, with most sales being Gonal-F, and told CNN patient savings would soon surpass $100 million. Those figures come from the manufacturer and are not independently audited.
Medication Is a Slice of the Bill, Not the Bill
This is where the two promises come apart, and it is the single most useful thing for a patient to understand before budgeting.
A full IVF cycle can run from about $12,000 to $25,000, according to figures the White House cited when the executive order was signed, and multiple cycles are often needed. Egg retrieval, anesthesia, monitoring ultrasounds, embryology laboratory work, embryo transfer, genetic testing, and storage fees are untouched by the drug agreement. MedicalDaily's breakdown of current IVF costs puts medications at roughly $3,000 to $8,000 per cycle depending on protocol.
The discount is also narrower than the headline number suggests. It covers Gonal-F, Cetrotide, and Ovidrel, and patients whose protocols use Follistim or Menopur need another source for those. The American Society for Reproductive Medicine has noted it applies to a narrow subset of drugs within a much broader cost structure.
The Employer Pathway Carries No Mandate and No Subsidy
The second announced initiative was aimed at employers, and its practical reach is easy to overstate.
An analysis by KFF, a nonpartisan health policy research organization, found the guidance did not create a new benefit category. It clarified how employers may offer fertility benefits under existing excepted-benefit rules. Some employers were already doing so. Participation is voluntary; there is no mandate, and no federal subsidy or tax incentive accompanies it.
One of the clarified pathways, an excepted-benefit health reimbursement account, caps employer contributions at $2,150, which KFF notes would, on average, cover about one-tenth of the cost of a single cycle. A proposed rule in 2026 aimed to encourage more voluntary employer uptake, but it likewise imposes no requirement.
Existing coverage remains uneven. The White House itself noted that only about a quarter of employers report offering IVF coverage, and KFF's employer survey finds coverage far more common at the largest firms than at midsize ones. State insurance mandates do not apply to self-funded plans, which cover roughly two-thirds of workers with employer-sponsored insurance. Medicaid does not provide comprehensive IVF coverage in any state.
KFF has concluded that without a subsidy, mandate, or employer incentive, the announced measures are unlikely to close current gaps in access. Establishing a mandate or subsidy would require Congress, and legislation to create a national right to IVF has not advanced.
One further consequence matters for patients comparing clinics. KFF reported that staff of the CDC division that runs the national assisted reproductive technology surveillance system, which publishes clinic-level success rates, were laid off. That data was used to evaluate one clinic against another.
Practical Steps for Patients Paying Out of Pocket This Cycle
Check insurance before assuming the federal discount is the best price. The site itself notes an insurance copay may be lower than its cash price.
Ask the clinic's financial coordinator whether the prescribed protocol uses the three discounted brand-name drugs, and whether remaining medications can be sourced separately. Combining sources often beats using one.
Request an itemized cost estimate covering retrieval, anesthesia, laboratory fees, transfer, testing, and storage before signing anything, and ask what a second cycle would cost. Ask about multi-cycle packages, clinic financial assistance, and manufacturer compassionate care programs, which predate the federal deal and may still apply.
Patients should not delay time-sensitive treatment waiting for coverage policy to change. Fertility declines with age, and no pending federal action would alter a patient's costs this year. Anyone weighing timing should have that conversation with a reproductive endocrinologist rather than a policy tracker.
Key Questions Answered
Is IVF free now? No. No federal law or regulation requires the government or insurers to cover IVF. What exists is a discount on three fertility medications and voluntary pathways for employers to offer fertility benefits.
How much did fertility drug prices actually fall? Gonal-F, with a list price above $900, is listed at $168. EMD Serono says patients using all three of its therapies in a typical protocol receive an 84 percent discount off list prices.
Which drugs are covered by the discount? Gonal-F, Cetrotide, and Ovidrel, all made by EMD Serono. Protocols using Follistim, Menopur, or other medications require a separate source for those drugs.
Does the discount meaningfully reduce total IVF cost? It reduces one component. A cycle can run from about $12,000 to $25,000, and multiple cycles are often needed. Retrieval, anesthesia, laboratory work, transfer, genetic testing, and storage are unaffected.
Do employers have to offer fertility benefits now? No. The federal guidance clarified existing pathways employers may use voluntarily. There is no mandate, no subsidy, and no tax incentive attached.
What would it take to make IVF broadly covered? Congressional action. A mandate or subsidy requires legislation, and bills to create a national right to IVF have not advanced.
Should someone delay treatment while waiting for policy to change? Fertility treatment is time-sensitive, and no pending federal action would change costs this year. Timing decisions belong in a conversation with a reproductive endocrinologist.
